TIMI 37A

TIMI 37A evaluated the efficacy, safety, and pharmacokinetics of INO-1001, a poly(ADP-ribose) polymerase in patients with ST-segment elevation myocardial infarction.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Morrow, D. A., Brickman, C. M., Murphy, S. A., Baran, K., Krakover, R., Dauerman, H., Kumar, S., Slomowitz, N., Grip, L., McCabe, C. H., Salzman, A. L. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial J Thromb Thrombolysis. 2009;27(4):359-64. Abstract